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EARLY CRT MONITORING USING
TIME-DOMAIN OPTICAL COHERENCE
TOMOGRAPHY DOES NOT ADD TO
VISUAL ACUITY FOR PREDICTING VISUAL
LOSS IN PATIENTS WITH CENTRAL
RETINAL VEIN OCCLUSION TREATED
WITH INTRAVITREAL RANIBIZUMAB
A Secondary Analysis of Trial Data
KATY J. L. BELL, PHD,*† ANDREW HAYEN, PHD,‡ PAUL GLASZIOU, PHD,†
ANDREW S. MITCHELL, MMEDSCI,§ MARIA FARRIS, BSC,¶ JONATHAN WRIGHT, MSC,**
HANS-PETER DUERR, PHD,†† PAUL MITCHELL, PHD,‡‡ LES IRWIG, PHD*
Purpose: Our primary purpose was to assess the clinical (predictive) validity of central
retinal thickness (CRT) and best corrected visual acuity (BCVA) at 1 week and 1 month after
starting treatment with ranibizumab for central retinal vein occlusion. The authors also
assessed detectability of response to treatment.
Methods: The authors used data from 325 participants in the CRUISE study, which
included measurement of time-domain CRT and BCVA at baseline, 1 week, 1 month, and 6
months postrandomization. Analysis of covariance models were ﬁtted to assess clinical
validity, and distributions of change were constructed to assess detectability of response.
Results: There was no evidence that 1-week CRT, and very strong evidence that 1-
week BCVA were associated with baseline-adjusted BCVA at 6 months (P = 0.17 and P ,
0.001, respectively). There was strong evidence that both 1-month CRT and 1-month
BCVA were associated with baseline-adjusted 6-month BCVA (P = 0.005 and P , 0.001,
respectively), but simultaneous adjustment found evidence of independent association
only for BCVA (P = 0.71 and P , 0.001 for CRT and BCVA, respectively). Detectability of
response tended to be higher for CRT than BCVA at 1 week and 1 month but by 6 months
these were equivalent for CRT and BCVA.
Conclusion: In this study, BCVA monitoring of treated central retinal vein occlusion patients
seemed more informative than time-domain optical coherence tomography monitoring.
RETINA 37:509–514, 2017
Treatment of central retinal vein occlusion with in-travitreal vascular endothelial growth factor inhib-
itors such as ranibizumab has been shown to improve
clinically relevant outcomes, including visual acuity,
visual functioning, and reading speed.1–3 Optical
coherence tomography (OCT) has emerged in recent
years as a way to measure anatomical changes in the
retina and other eye tissues.4,5 Central retinal thickness
(CRT) measured after retinal vein occlusion is used to
estimate the extent of macular edema to judge initial
prognosis and need for retreatment. Central retinal
thickness is also used to monitor the response to treat-
ment, but the value of this practice is not known.
The best monitoring test may be chosen on the basis
of technical factors6; the two criteria relevant to central
retinal vein occlusion are 1) clinical (predictive) valid-
ity, that is, how well the test predicts visual acuity and
other patient-centered outcomes; and 2) detectability of
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response, that is, how clearly and rapidly the test
changes after starting therapy (“signal”) relative to
background within-patient variability (“noise”). Clinical
validity is the most important, and it is usually not
worth using a monitoring test without this.6
Morphological changes detected by OCT, such as
CRT, hypothetically occur before changes in visual
acuity are detected. However, the graphical depiction
of changes in both best corrected visual acuity
(BCVA) and CRT seen in the CRUISE randomized
controlled trial suggest that there is no difference in the
onset of treatment effects observed at 1 week after
treatment, although the maximal effect on BCVA
(approximately 5 months) may lag behind the maximal
effect on CRT (approximately 7 days).1 Best corrected
visual acuity (or at least presenting VA), is routinely
measured at follow-up clinics and may itself be used to
monitor patients on treatment. For CRT to be useful as
a monitoring test, it needs to have an incremental ben-
eﬁt above and beyond BCVA. That is, for OCT to be
useful for making decisions about treatment and prog-
nosis, it needs to provide information which is addi-
tional to that already available to the clinician, which
includes information on the patient’s visual acuity.
Our primary aim was to assess the clinical validity
of CRT measured at 1 week and 1 month after starting
treatment, and whether there was incremental beneﬁt
beyond measuring BCVA, in patients treated with
ranibizumab for central retinal vein occlusion. We also
evaluated the responsiveness of CRT and BCVA to
treatment.
Methods
Study Design and Sample
The study design and population of CRUISE has
been described previously.1,7 In brief, in CRUISE,
participants provided informed consent and were ran-
domized to 0.3 mg, 0.5 mg ranibizumab, or sham
intraocular injection monthly for 6 months, with an
additional 6 months of follow-up (total 12 months),
where all study arms received ranibizumab if they
met prespeciﬁed criteria. The current analysis is lim-
ited to the ﬁrst 6 months. Study participants were
adults with foveal center–involved macular edema sec-
ondary to central retinal vein occlusion (CRVO) diag-
nosed within 12 months before study initiation, BCVA
20/40 to 20/320 Snellen equivalent using the Early
Treatment Diabetic Retinopathy Study (ETDRS)
charts, mean CRT $250 mm from 2 OCT measure-
ments (at screening and randomization). One eye per
participant was chosen as the study eye. Only the
study eye was treated with either ranibizumab injec-
tion or sham injection and is included in this analysis.
Measurement of Predictor and Outcome Tests
Best corrected visual acuity was measured by the
masked investigating physician at individual study sites
using the ETDRS chart.8 Best corrected visual acuity in
the study eye was based on the ETDRS visual acuity
chart and assessed at a starting test distance of 4 meters.
Central retinal thickness was measured on OCT by
masked graders at the University of Wisconsin Fundus
Photograph Reading Center (UWFPRC; Madison, WI),
using Zeiss Stratus 3 software with the FastMac pro-
tocol (Carl Zeiss Meditec, Inc., Dublin, CA). Central
retinal thickness was recorded as the center point thick-
ness using time-domain Stratus 3 software (Carl Zeiss
Meditec, Inc.), unless there was an error in computer
recognition of the outer or inner boundaries of the retina
or the center point. If that occurred, the grader deter-
mined CRT with a caliper.
Statistical Methods
We used the following methods to assess clinical
validity of CRT. We included participants with avail-
able data on both BCVA and CRT at each of baseline, 1
week, 1 month, and 6 months. As a preliminary step,
we constructed scatterplots and calculated correlation
coefﬁcients of CRT and BCVA at 1 week or 1 month
versus change in BCVA from baseline to 6 months. We
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built linear regression models using analysis of covari-
ance to assess baseline-adjusted BCVA at 6 months.9
The dependent variable in these models was 6 months
BCVA, and baseline BCVA was included as a covari-
ate, along with treatment and age. We used these mod-
els to estimate associations between baseline-adjusted 6
months BCVA and each of the following potential
monitoring variables: CRT, CRT change from baseline,
BCVA, and BCVA change from baseline, each mea-
sured at 1 week or 1 month. For signiﬁcant CRT or
BCVA monitoring variables, we also estimated associ-
ations after adjustment for the other monitoring variable
at the same time point. These models allowed us to
assess incremental beneﬁt—how much information
one monitoring variable (CRT or BCVA) was adding
to that already provided by the other. Likelihood ratio
tests were used to assess statistical signiﬁcance.
Finally, we also assessed detectability of response for
changes in OCT and BCVA from baseline to 1 week, 1
month, and 6 months, using a method that directly
compares change distributions in active and placebo
arms of the trial.10 The detectability of response is the
ratio of signal (true treatment effects) to noise (random
variation). The true mean response to treatment was
estimated from the difference in mean changes between
treated and placebo groups; the true between-person
variation in treatment effects was estimated from the
difference in variances of change in treated and placebo
groups. Background within-person variation was esti-
mated from the variance of change in the placebo group.
We used the estimates of signal (true mean change or
true between-person variation) and noise (background
within-person variation) to estimate signal:noise ratios,
which indicated the detectability of response.
Ethics Committee approval was not required for this
secondary analysis of de-identiﬁed data.
Results
We included 325 of the 392 participants in the trial,
who had data available on both BCVA and CRT at each
of baseline, 1 week, 1 month, and 6 months. Summary
characteristics of these participants are presented in Table
1. The low-dose ranibizumab group had more partici-
pants with the necessary data available on BCVA and
CRT than either the sham group or the high-dose group,
but the three groups were otherwise broadly similar.
Clinical Validity
The correlation between CRT and BCVA measured
at 1 week and 1 month with change in BCVA from
baseline to 6 months is shown in Supplemental Dig-
ital Content 1 (see level of CRT or BCVA at 1 week
and 1 month, http://links.lww.com/IAE/A502 and
http://links.lww.com/IAE/A503) and Supplemental
Digital Content 2 (see change in CRT from baseline
to 1 week and to 1 month, http://links.lww.com/IAE/
A500 and http://links.lww.com/IAE/A501). These
plots suggest that the association of each potential
monitoring test with change in visual acuity at
6 months is at most modest.
These potential associations were then analyzed in the
analysis of covariance models, with adjustment for
baseline BCVA, age, and treatment. There was no
evidence that CRT measured at 1 week was associated
with baseline-adjusted BCVA at 6 months (P = 0.17 for
level and 0.79 for change from baseline), and this was
not explored further. In contrast, there was very strong
evidence that BCVA measured at 1 week was associated
with baseline-adjusted BCVA at 6 months (P , 0.001).
The associations of the measurement of CRT or
BCVA at 1 month with baseline-adjusted BCVA at 6
months are summarized in the ﬁrst row of Table 2
(baseline-adjusted BCVA at 6 months is equivalent
to 6 months change in BCVA from baseline). There
was strong evidence that 1 month CRT level had an
association, but not CRT change from baseline (P =
0.005 and P = 0.09, respectively). For each SD
increase in CRT level, there was a decrease in
baseline-adjusted BCVA at 6 months by 0.13 letters
(95% CI: decrease by 0.046–0.21 letters). However,
after adjusting for 1 month BCVA, there was no lon-
ger evidence of an association (P = 0.71). This indi-
cates that 1 month CRT had no incremental beneﬁt in
predicting baseline-adjusted BCVA at 6 months. There
Table 1. Baseline Characteristics of 325 Included Participants
Characteristic Sham (n = 101)
Ranibizumab
0.3 mg (n = 117) 0.5 mg (n = 107)
Age, years, mean (SD) 64.8 (13.2) 70.2 (11.2) 68.6 (11.6)
Male, n (%) 57 (56) 64 (55) 65 (61)
White ethnicity, n (%) 89 (88) 97 (83) 89 (84)
BCVA (mean ETDRS letter score, SD) 49.7 (14.5) 47.8 (14.4) 49.1 (14.0)
Approximate Snellen equivalent 20/100 20/100 20/100
CRT, mm, mean (SD) 595.7 (149.4) 591.4 (163.2) 600.0 (157.3)
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was very strong evidence that 1 month BCVA level
was associated with baseline-adjusted BCVA at 6
months, which remained after adjusting for 1 month
CRT level (P , 0.001 before and after adjusting for
CRT). For each SD increase in BCVA at 1 month,
there was an increase in baseline-adjusted BCVA at
6 months of 0.25 letters (95% CI: 0.17–0.33 letters).
The results within the different treatment groups are
presented in Table 2 (lower rows). There was less
evidence for associations between 1 month CRT and
baseline-adjusted BCVA at 6 months in both of the
treatment groups than for the population as a whole
presented above. However, in the sham-treated group,
there was very strong evidence of an association (P ,
0.001), and this remained signiﬁcant after adjusting for
1 month BCVA (P = 0.03). This indicates that 1 month
CRT may have incremental beneﬁt in predicting
baseline-adjusted BCVA at 6 months for patients not
on active treatment.
Sensitivity analyses using log transformed data gave
similar results.
Detectability of Response to Treatment
The detectability of CRT and BCVA responses to
treatment were estimated from data presented in Figure 1
and Supplemental Digital Content 3 (see Appendix
Table, http://links.lww.com/IAE/A504). These show
the distributions of change in CRT and BCVA from
baseline to 1 week, 1 month, and 6 months, stratiﬁed
by treatment group. The differences in means for treated
groups and sham-treated group at each time point reﬂects
the true mean treatment effect (or the expected effect).
The differences in the variances of the distributions re-
ﬂects the true between-person variation in treatment ef-
fects (distributions are wider in treated groups than
sham-treated group). The variance of the distribution in
the sham-treated group reﬂects random within-person
variation (noise). Detection of response to treatment at
1 week and 1 month appeared more likely with CRT
than BCVA (signal:noise ratios were higher for CRT
than BCVA for both detection of the expected ranibizu-
mab effect and detection of true between-person differ-
ences). However, by 6 months, there appeared to be no
difference in the detectability of response.
Discussion
In this study of 325 participants of a randomized
controlled trial, we found no evidence overall that CRT
measured 1 week or 1 month after starting treatment
had incremental beneﬁt in predicting baseline-adjusted
6 months BCVA, for either 0.3 mg or 0.5 mg
ranibizumab. At least for these intervals, CRT seems
to fail the critical “clinical validity” criterion needed for
a monitoring test in that it provides no incremental
value beyond information already provided by contem-
poraneous BCVAmeasurement. The absence of clinical
validity means that, although responses to treatment are
more likely to be detected with CRT than BCVA (high-
er signal:noise ratios), these responses do not have
major clinical relevance. In contrast, BCVA measured
at 1 week and 1 month after starting treatment strongly
predicted baseline-adjusted BCVA at 6 months and
may be of potential value for monitoring patients.
The detectability of response to treatment was
poorer for BCVA than CRT within the ﬁrst month,
and ratios for signal (treatment effects) to noise
(background variation) were #1. This indicates that,
at best, treatment and chance contributed equally to an
observed change in BCVA. However, this is better
than many other measures commonly used for clinical
monitoring such as blood pressure, cholesterol, and




Monitoring Variable Adjusted for Other Monitoring Variable
Treatment N
Estimate (Change in ETDRS
Letter Score)* P†
Estimate (Change in ETDRS
Letter Score)* P†
All participants 325 CRT 1 month 20.13 (20.21 to 20.046) 0.005 20.039 (20.12 to 0.044) 0.71
BCVA 1 month 0.25 (0.17–0.33) ,0.001 0.23 (0.15–0.32) ,0.001
Sham 101 CRT 1 month 20.30 (20.47 to 20.13) ,0.001 20.24 (20.41 to 20.07) 0.03
BCVA 1 month 0.24 (0.10–0.38) ,0.001 0.19 (0.04–0.33) ,0.001
0.3 mg 117 CRT 1 month 20.13 (20.32 to 0.06) 0.10 20.003 (20.21 to 0.20) 0.06
BCVA 1 month 0.24 (0.10–0.39) ,0.001 0.24 (0.08–0.40) ,0.001
0.5 mg 107 CRT 1 month 20.16 (20.32 to 20.006) 0.05 20.07 (20.22 to 0.09) 0.45
BCVA 1 month 0.30 (0.18–0.42) ,0.001 0.29 (0.16–0.41) ,0.001
*Estimated changes in BCVA (ETDRS letter score) at 6 months per SD in the monitoring variable are from models where effects of
baseline BCVA, age, and treatment are ﬁxed.
†P value is based on likelihood ratio test.
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bone mineral density.10–15 The ability to detect a true
response to treatment using BCVA is likely to be
improved using repeat measurements.12,14,16,17
Central retinal thickness did have incremental
beneﬁt (and clinical validity) in the sham-treated
group, suggesting that measurements made before
starting treatment may usefully add to BCVA meas-
urements in predicting later deterioration in BCVA.
We did not directly assess the usefulness of pre-
treatment measurements for predicting response to
treatment, but this might be investigated by looking at
how baseline measurements of CRT and BCVA
modify the effect of treatment on BCVA at 6 months.
Strengths of our study are that rigorous statistical
methods have been applied to data derived from a large
RCT. A limitation of our study is that the assessment
of OCT was based on quantitative measures using
time-domain (Stratus) technology. Qualitative and
quantitative measures using spectral domain technol-
ogy may be more relevant clinically.18,19 However, the
evidence showing treatment effectiveness is from the
same trial data, and using the same type of OCT ma-
chines, as we have used here. Furthermore, there is
likely to be at least a modest correlation between time
and spectral domain machines, and between quantita-
tive and qualitative ﬁndings. Our estimates of “noise”
are likely to be “best case” scenarios and within-
person variation may be larger in clinical practice
where there may be larger differences in OCT mea-
surement of an individual at baseline and follow-up,
possibly including different instruments.
Our ﬁndings build on those of a cross-sectional
analysis of baseline data from 262 patients with
CRVO who participated in the Standard Care versus
Corticosteroid for REtinal Vein Occlusion Study. The
authors found only a modest correlation between time-
domain CRT and BCVA, both measured before
starting the study treatment (correlation coefﬁcient =
20.27; 95% CI: 20.38 to 20.16), and concluded that
OCT cannot reliably substitute for visual acuity meas-
urements.20 This estimate is in keeping with our esti-
mated correlation coefﬁcients (Figure 1), and our
Fig. 1. A. Change in CRT from baseline to Week 1; (B) change in BCVA from baseline to Week 1; (C) change in CRT from baseline to Month 1; (D)
change in BCVA from baseline to Month 1; (E) change in CRT from baseline to Month 6; (F) change in BCVA from baseline to Month 6.
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further longitudinal analysis shows that CRT actually
has no incremental beneﬁt over BCVA in predicting
the baseline-adjusted 6-month BCVA.
A possible explanation of these results is that OCT
may fail to detect any underlying ischemic maculop-
athy which persists despite treatment, and which
results in failure of vision to improve. However, an
early vision response is likely to indicate underlying
health of the macula on treatment and that the vision
was able to be preserved with treatment.
The most immediate implication of this report for
clinicians and policymakers is that monitoring CRT in
patients treated with ranibizumab for CRVO does not
add incremental beneﬁt over standard measurements
of vision, at least using time-speciﬁc OCT. This
ﬁnding is likely to also apply to CRT monitoring of
other treatments for CRVO. This report also more
generally demonstrates how published criteria on how
to assess monitoring tests6 may be used to appraise
tests used in patients with eye disease or other chronic
conditions to inform clinical and funding decisions.
Results based on individual patient data such as we
have presented here allow for more in-depth explora-
tion of how well each test meets the monitoring criteria
and testing of the statistical assumptions that underpin
analysis. Where these types of data are not available,
appraisal may still be possible using published sum-
mary data from trials, particularly if there are sufﬁcient
data to enable metaanalysis.
Future research may address the extent to which
spectral domain technology differs from time domain
and whether there is likely to be incremental beneﬁt to
measurements made with these newer instruments
over measurements of visual acuity.
Conclusions
There is no evidence to support early CRT moni-
toring with time-domain OCT after starting ranibizu-
mab to treat CRVO, at least in addition to the
information obtained from BCVA.
Key words: evidence-based medicine, intravitreal
injections, macular edema, retinal vein occlusion,
tomography, optical coherence, visual acuity.
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